Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2014, Article ID 516593, 7 pages
Research Article

Anti-hnRNP B1 (RA33) Autoantibodies Are Associated with the Clinical Phenotype in Russian Patients with Rheumatoid Arthritis and Systemic Sclerosis

1Department of Rheumatology, Almazov Medical Research Centre, 197341 St. Petersburg, Russia
2Laboratory of Autoimmune Diagnostics, St. Petersburg Pavlov State Medical University, 197022 St. Petersburg, Russia
3Eichwald Department of Therapy and Rheumatology, Mechnikov Northwestern State University, 191015 St. Petersburg, Russia
4Faculty of Science, Brandenburg University of Technology Cottbus-Senftenberg, Großenhainer Straße 57, 01968 Senftenberg, Germany
5R/D, Medipan GmbH, Dahlewitz, 15827 Berlin, Germany
6Institute of Liver Studies, Division of Transplantation Immunology and Mucosal Biology, King’s College London School of Medicine at King’s College Hospital, London SES 9RJ, UK

Received 14 January 2014; Revised 9 April 2014; Accepted 9 April 2014; Published 4 May 2014

Academic Editor: Michael Mahler

Copyright © 2014 Aleksey Maslyanskiy et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Heterogeneous nuclear ribonucleoproteins (hnRNPs) are potent autoantigenic targets in systemic autoimmune rheumatic diseases (SARD). Loss of tolerance to the RA33 complex consisting of hnRNP A2 and its alternatively spliced variants B1 and B2 has been the interest of rheumatologists. A novel ELISA for the detection of anti-hnRNP B1 autoantibodies has been developed to investigate the prevalence thereof in 397 patients with SARD, including patients with rheumatoid arthritis (RA), spondyloarthropathy (SPA), juvenile chronic arthritis, systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and Sjögren’s syndrome (SS), in comparison to 174 controls. Anti-hnRNP B1 autoantibodies were significantly more prevalent in patients with SARD than controls (47/397, 11.8% versus 2/174, 1.1%; ). In particular, anti-hnRNP B1 were found more frequently in the disease cohorts than in the controls and were present in 24/165 (14.5%) patients with RA, 6/58 (10.3%) SPA, 11/65 (16.9%) SSc, and 4/50 (8.0%) SLE. In RA patients, anti-hnRNP B1 autoantibodies correlated significantly with C-reactive protein levels and erythrocyte sedimentation rate, while in patients with SSc it was associated with features of arterial wall stiffness and presence of hypertension. Anti-hnRNP B1 autoantibodies occur in SARD and seem to be correlated with distinct clinical characteristics in patients with RA and SSc.